The filing content cuts off before the financial statements and MD&A sections, but there is sufficient substantive disclosure content (the cover page data, share count, filing period, company identity, and the detailed risk factor list) to exceed 150 words of substantive content. I'll proceed with what is available.

IRadimed Corporation filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on October 30, 2026, covering the company's third fiscal quarter.

Key Highlights

  • Shares outstanding: The registrant reported 12,788,153 shares of common stock, par value $0.0001 per share, outstanding as of October 30, 2026.
  • Filer status: IRadimed is classified as a non-accelerated filer and a smaller reporting company, according to the filing.
  • Exchange listing: The common stock trades on NASDAQ:IRMD on the NASDAQ Global Market.
  • Reporting period: The quarterly report covers the three and nine months ended September 30, 2026, with comparative periods ending September 30, 2025.
  • Shell company status: The registrant confirmed it is not a shell company as defined in Rule 12b-2 of the Exchange Act.
  • AI and tariff risks flagged: The filing identifies risks related to the integration of Artificial Intelligence and Machine Learning into products, as well as the impact of tariffs, trade restrictions, and export controls, among other risk factors.

IRadimed's Third-Quarter 2026 Filing: Key Disclosures and Risk Factors

IRadimed Corporation, a Delaware-incorporated company headquartered at 12705 Ingenuity Drive, Orlando, Florida 32826, filed its Form 10-Q for the quarterly period ended September 30, 2026, with the Commission File Number 001-36534. The filing confirms the company had 12,788,153 shares of common stock outstanding as of October 30, 2026, each carrying a par value of $0.0001. The company trades on the NASDAQ Global Market under the symbol IRMD.

The filing's cautionary note identifies a broad set of risk factors that the company says could cause actual results to differ materially from any forward-looking statements. Among those risks, the company specifically calls out "the risks associated with the integration of Artificial Intelligence ('AI') or Machine Learning ('ML') into our products or business, including algorithmic errors or bias, uncertain regulatory requirements applicable to AI-enabled medical devices, data privacy and security concerns arising from the use of AI or ML, and potential liability arising from AI-driven product decisions or recommendations." The filing also flags "the impact of tariffs, trade restrictions, export controls, and changes in trade policy, which could increase the cost of components and raw materials used in our products, disrupt our supply chain, limit our ability to sell products in international markets, or otherwise adversely affect our business and results of operations."

Additional risks disclosed include reliance on FDA regulatory approvals and 510(k) clearances, dependence on a limited number of products, supply chain integrity, geopolitical risks, and cybersecurity threats. The company notes it has filed all required reports with the SEC during the preceding 12 months and has submitted all required Interactive Data Files electronically. All forward-looking statements in the filing, the company notes, are subject to the risks and uncertainties set out in the document.

What Was Disclosed

IRadimed Corporation submitted its Form 10-Q for the quarter ended September 30, 2026, disclosing 12,788,153 shares outstanding and classifying itself as a non-accelerated, smaller reporting company. The filing outlines risk factors including AI integration, tariff exposure, and regulatory compliance.